| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | |
|---|---|---|---|---|
| Research and development | 12,702 | 11,262 | 4,375* | |
| Acquired in-process research and development | - | - | 17,022* | |
| Milestone liability change in fair value | 175 | -929 | - | |
| General and administrative | 6,576 | 6,881 | 4,170* | |
| Total operating expenses | 19,453 | 17,214 | 25,566 | |
| Loss from operations | -19,453 | -17,214 | -25,566* | |
| Other income, net | 446 | 586 | 309* | |
| Sermonix pre-funded warrant change in fair value | - | 16,320 | 1,145* | |
| Net loss | -19,007 | -32,948 | -26,402* | |
| Unrealized (loss) gain on available-for-sale securities | 4 | -9 | -1* | |
| Comprehensive loss attributable to common stockholders | -19,003 | -32,957 | -26,403 | |
| Basic EPS | -0.8 | -1.73 | -6.175 | |
| Diluted EPS | -0.8 | -1.73 | -6.175 | |
| Basic Average Shares | 23,726,211 | 19,027,087 | 4,275,762 | |
| Diluted Average Shares | 23,726,211 | 19,027,087 | 4,275,762 | |
LeonaBio, Inc. (LONA)
LeonaBio, Inc. (LONA)